These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 31465304)
41. Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection. El Chehab H; Le Corre A; Agard E; Ract-Madoux G; Coste O; Dot C Eur J Ophthalmol; 2013; 23(3):277-83. PubMed ID: 23161177 [TBL] [Abstract][Full Text] [Related]
42. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Liu JH; Kripke DF; Weinreb RN Am J Ophthalmol; 2004 Sep; 138(3):389-95. PubMed ID: 15364220 [TBL] [Abstract][Full Text] [Related]
43. Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma. Tamada Y; Taniguchi T; Murase H; Yamamoto T; Kitazawa Y J Ocul Pharmacol Ther; 2001 Feb; 17(1):19-25. PubMed ID: 11322634 [TBL] [Abstract][Full Text] [Related]
44. Association between Glaucoma Medication Usage and Dry Eye in Taiwan. Chen HY; Lin CL; Tsai YY; Kao CH Optom Vis Sci; 2015 Sep; 92(9):e227-32. PubMed ID: 26192153 [TBL] [Abstract][Full Text] [Related]
45. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Kass MA; Heuer DK; Higginbotham EJ; Johnson CA; Keltner JL; Miller JP; Parrish RK; Wilson MR; Gordon MO Arch Ophthalmol; 2002 Jun; 120(6):701-13; discussion 829-30. PubMed ID: 12049574 [TBL] [Abstract][Full Text] [Related]
46. Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase after Cataract Surgery in Eyes with Glaucoma. Hayashi K; Yoshida M; Sato T; Manabe SI Am J Ophthalmol; 2019 Sep; 205():91-98. PubMed ID: 30902694 [TBL] [Abstract][Full Text] [Related]
47. Association of Systemic Medication Use with Glaucoma and Intraocular Pressure: The European Eye Epidemiology Consortium. Vergroesen JE; Schuster AK; Stuart KV; Asefa NG; Cougnard-Grégoire A; Delcourt C; Schweitzer C; Barreto P; Coimbra R; Foster PJ; Luben RN; Pfeiffer N; Stingl JV; Kirsten T; Rauscher FG; Wirkner K; Jansonius NM; Arnould L; Creuzot-Garcher CP; Stricker BH; Keskini C; Topouzis F; Bertelsen G; Eggen AE; Bikbov MM; Jonas JB; Klaver CCW; Ramdas WD; Khawaja AP; Ophthalmology; 2023 Sep; 130(9):893-906. PubMed ID: 37150298 [TBL] [Abstract][Full Text] [Related]
48. A Review of New Medications and Future Directions of Medical Therapies in Glaucoma. Jiang Y; Ondeck C Semin Ophthalmol; 2020 Aug; 35(5-6):280-286. PubMed ID: 33019870 [TBL] [Abstract][Full Text] [Related]
49. Effect of glaucoma medications on 24-hour intraocular pressure-related patterns using a contact lens sensor. Mansouri K; Medeiros FA; Weinreb RN Clin Exp Ophthalmol; 2015 Dec; 43(9):787-95. PubMed ID: 26152693 [TBL] [Abstract][Full Text] [Related]
50. Glaucoma severity and medication adherence in a county hospital population. Ung C; Zhang E; Alfaro T; Murakami Y; Zhang M; Seider MI; Lin SC; Singh K Ophthalmology; 2013 Jun; 120(6):1150-7. PubMed ID: 23453512 [TBL] [Abstract][Full Text] [Related]
51. A case hypersensitive to bimatoprost and dexamethasone. Li X; Liu G; Wang Y; Yu W; Xiang H; Liu X J Ocul Pharmacol Ther; 2011 Oct; 27(5):519-23. PubMed ID: 21936632 [TBL] [Abstract][Full Text] [Related]
53. The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications. Higginbotham EJ; Diestelhorst M; Pfeiffer N; Rouland JF; Alm A Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S133-40. PubMed ID: 12204710 [TBL] [Abstract][Full Text] [Related]
54. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Fukushima A; Suganami H; Araie M; Acta Ophthalmol; 2016 Feb; 94(1):e26-34. PubMed ID: 26338317 [TBL] [Abstract][Full Text] [Related]
55. Is the observed lowering of intraocular pressure due to treatment? Thomas R; Mengersen K Indian J Ophthalmol; 2013 Mar; 61(3):119-21. PubMed ID: 23514647 [TBL] [Abstract][Full Text] [Related]
56. The safety and efficacy of glaucoma medication in the pediatric population. Coppens G; Stalmans I; Zeyen T; Casteels I J Pediatr Ophthalmol Strabismus; 2009; 46(1):12-8. PubMed ID: 19213271 [TBL] [Abstract][Full Text] [Related]
57. Monocular trial of intraocular pressure-lowering medication: a prospective study. King AJ; Uppal S; Rotchford AP; Lakshumanan A; Abedin A; Henry E Ophthalmology; 2011 Nov; 118(11):2190-5. PubMed ID: 21724262 [TBL] [Abstract][Full Text] [Related]
58. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study. Lopes JF; Hubatsch DA; Amaris P BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363 [TBL] [Abstract][Full Text] [Related]
59. Effects of several anti-glaucoma medications on the circadian intraocular pressure fluctuations in patients with primary open-angle glaucoma. Tanaka S; Watanabe M; Inatomi S; Umeda K; Yoshida K; Ohguro I; Ohguro H J Ocul Pharmacol Ther; 2014 Feb; 30(1):12-20. PubMed ID: 24286181 [TBL] [Abstract][Full Text] [Related]
60. Influence of Treating Ocular Surface Disease on Intraocular Pressure in Glaucoma Patients Intolerant to Their Topical Treatments: A Report of 10 Cases. Dubrulle P; Labbé A; Brasnu E; Liang H; Hamard P; Meziani L; Baudouin C J Glaucoma; 2018 Dec; 27(12):1105-1111. PubMed ID: 30489502 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]